VEGFA and nonpapillary renal cell carcinoma: Over the past two decades, targeted antiangiogenesis therapies, including tyrosine kinase inhibitors (TKIs), have profoundly increased the survival time of patients, due to the abnormal hyperactivation of the vascular endothelial growth factor (VEGF) pathway commonly observed in ccRCC 3, which implies that understanding the pathogenesis of ccRCC forms the basis for attempts to identify novel treatment options 4.